Nkarta Inc (NASDAQ:NKTX) — Market Cap & Net Worth
Market Cap & Net Worth: Nkarta Inc (NKTX)
Nkarta Inc (NASDAQ:NKTX) has a market capitalization of $201.27 Million ($201.27 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #16620 globally and #3949 in its home market, demonstrating a -3.44% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Nkarta Inc's stock price $2.81 by its total outstanding shares 71624791 (71.62 Million). Also see balance sheet size of Nkarta Inc for a full breakdown of the balance sheet.
Nkarta Inc Market Cap History: 2020 to 2026
Nkarta Inc's market capitalization history from 2020 to 2026. Data shows change from $4.40 Billion to $201.27 Million (-36.75% CAGR). Also see Nkarta Inc cash conversion from operations for how efficiently the company converts equity into cash flow.
Index Memberships
Nkarta Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.67 Trillion | 0.01% | #462 of 976 |
|
NASDAQ Composite
IXIC
|
$41.95 Trillion | 0.00% | #1642 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.88 Trillion | 0.01% | #229 of 263 |
Weight: Nkarta Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Nkarta Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Nkarta Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check today's stock price for Nkarta Inc for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
11435781.57x
Nkarta Inc's market cap is 11435781.57 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $4.40 Billion | $385.00 | -$91.36 Million | 11435781.57x | N/A |
Competitor Companies of NKTX by Market Capitalization
Companies near Nkarta Inc in the global market cap rankings as of September 18, 2026. Review NKTX goodwill-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Nkarta Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
Nkarta Inc Historical Marketcap From 2020 to 2026
Between 2020 and today, Nkarta Inc's market cap moved from $4.40 Billion to $ 201.27 Million, with a yearly change of -36.75%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $201.27 Million | +51.89% |
| 2025 | $132.51 Million | -25.70% |
| 2024 | $178.35 Million | -62.27% |
| 2023 | $472.72 Million | +10.18% |
| 2022 | $429.03 Million | -60.98% |
| 2021 | $1.10 Billion | -75.03% |
| 2020 | $4.40 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Nkarta Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $201.27 Million USD |
| MoneyControl | $201.27 Million USD |
| MarketWatch | $201.27 Million USD |
| marketcap.company | $201.27 Million USD |
| Reuters | $201.27 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Nkarta Inc
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myo… Read more